Discussing warning signs from Dendreon, and other worrisome companies, with Les Funtleyder, E Square Asset Management.
Joseph Pantginis, Roth Capital, has been negative on Dendreon for a long time, ahead of the drugmaker's bankruptcy protection filing.
Chris Anzalone, Arrowhead CEO, discusses current studies on the hepatitis B virus and its effect on the liver, and whether the company is gaining the confidence back of shareholders.
CNBC's Meg Tirrell reports on the increasing competition among pharma companies for the fight against hepatitis C.
The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.
CNBC's Meg Tirrell speaks to Alex Gorsky, Johnson & Johnson chairman & CEO, about helping military veterans transition from the battlefield into corporate America.
Jack Lief, Arena Pharmaceutical president & CEO, breaks down the company's Q3 earnings and discusses the outlook for its weight loss drug "Belviq."
AbbVie reported strong earnings on demand for its Humira drug and said it could deliver strong long-term growth without another big merger bid.
People may be worried that health-care costs will increase and become a trend, Aetna's CEO said he's not.
A nasty Wall Street divorce has touched two biotech CEOs and appears to have moved their company stocks down over drug use allegations.
We are focusing on three big divisions in the next five years - pharmaceuticals, generics and eye care., says Joe Jimenez, Novartis CEO, explaining how Novartis plans to benefit from partnering with other big pharma companies.
We are focusing on innovation, says Joe Jimenez, Novartis CEO, discussing the company's growth prospects and the top three drugs driving sales.
Shares of Sanofi tumbled around 7.4 percent early on Tuesday after the French drugmaker reported weaker-than-expected Q3 sales.
With some 84 million people in the U.S. struggling with obesity, investing in obesity stocks has become a Wall Street trend.
Researchers say they have developed a test that can diagnose Ebola within 30 minutes, the BBC reports.
Barbara Ryan, FTI Consulting, breaks down the numbers on Merck's quarterly results as the company appears to be reaping the rewards of R&D. Also a look ahead to Pfizer's earnings
Drug companies may be looking for legal protection amid a massive demand for Ebola vaccines, reports CNBC's Meg Tirrell.
Eli Lilly earnings plunged, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year forecast.
John Lechleiter, Eli Lilly CEO, crunches the numbers on his company's quarterly results and explains how a strong dollar is impacting global sales.
Paulson & Co, a shareholder in Allergan, urged the Botox maker to launch a bid for Shire after AbbVie walked away from a takeover, CNBC's Catherine Boyle reports.